Oleanolic acid (Synonyms: 齊墩果酸; Oleanic acid; Caryophyllin)

目錄號: HY-N0156 純度: ≥98.0%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計算器

Oleanolic Acid (Oleanic acid) 是一具有抗癌活性的天然化合物。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Oleanolic acid Chemical Structure

CAS No. : 508-02-1

1. 客戶無需承擔(dān)相應(yīng)的運輸費用。

2. 同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥154	In-stock
25 mg	￥140	In-stock
50 mg	￥230	In-stock
100 mg	￥380	In-stock
500 mg	￥900	In-stock
1 g	￥1260	In-stock
5 g	￥1550	In-stock
10 g		詢價
50 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Oleanolic acid:

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻

•Acta Pharm Sin B. 2024 Mar 18.
•PLoS Biol. 2024 June 27.
•Pharmacol Res. 2024 May 9:204:107208. [Abstract]
•Food Chem. 2022: 134807.
•Phytomedicine. 2023 Nov 11, 155208.
•Biomed Pharmacother. 2020 Mar;123:109752. [Abstract]
•Int Immunopharmacol. 2024 Jul 6:138:112617. [Abstract]
•Dev Biol. 2023 Sep 25;S0012-1606(23)00164-1. [Abstract]
•Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
•bioRxiv. 2023 Jun 3.

Oleanolic acid 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 MAP3K 亞型特異性產(chǎn)品:

查看所有亞型

MAP3K7/TAK1 MAP3K8 ASK2 MAP3K5/ASK1

查看 HIV 亞型特異性產(chǎn)品:

查看所有亞型

HIV HIV-1 HIV-2

生物活性
純度 & 產(chǎn)品資料
參考文獻

生物活性

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.

IC₅₀ & Target

ASK1

細胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
4T1	IC₅₀	514.1 μM Compound: 3; OA	Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
518A2	EC₅₀	> 30 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 28033541]
518A2	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
518A2	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
518A2	IC₅₀	> 60 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24361521]
518A2	EC₅₀	61.3 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
518A2	EC₅₀	64.3 μM Compound: OA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 26750249]
518A2	EC₅₀	64.3 μM Compound: 1; OA	Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
8505C	EC₅₀	> 30 μM Compound: 2	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 28033541]
8505C	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
8505C	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
8505C	IC₅₀	> 60 μM Compound: OA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
A2780	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A2780	EC₅₀	14 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 28033541]
A2780	EC₅₀	14 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 26750249]
A2780	IC₅₀	14 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	EC₅₀	14 μM Compound: 1; OA	Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A2780	EC₅₀	58.2 μM Compound: OA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
A-375	IC₅₀	328.8 μM Compound: 3; OA	Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	IC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	> 100 μM Compound: 1, oleanolic acid	Cytotoxicity against human A549 cells after 1 hr by MTT assay Cytotoxicity against human A549 cells after 1 hr by MTT assay	[PMID: 18343122]
A549	GI₅₀	> 100 μM Compound: 27	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
A549	IC₅₀	> 200 μM Compound: 4	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	EC₅₀	> 30 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 28033541]
A549	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
A549	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A549	IC₅₀	0.39 μM Compound: 1, OA	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23434227]
A549	IC₅₀	16.29 μM Compound: 1	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
A549	IC₅₀	19.94 μM Compound: OA	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
A549	IC₅₀	209 μM Compound: 10	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 15730243]
A549	IC₅₀	27 μM Compound: 4	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
A549	IC₅₀	41.65 μM Compound: 1; OA	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
A549	IC₅₀	6.4 μM Compound: OA	Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay	[PMID: 31718182]
A549	EC₅₀	64.1 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
A549	IC₅₀	64.26 μM Compound: 3; OA	Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	EC₅₀	72.3 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 26750249]
A549	IC₅₀	72.3 μM Compound: OA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	EC₅₀	72.3 μM Compound: 1; OA	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A549	IC₅₀	81.4 μM Compound: OA	Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
A549	IC₅₀	96.2 μM Compound: 10	Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge	[PMID: 15730243]
A549/TR	IC₅₀	> 200 μM Compound: 1; OA	Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549/T cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
B16	IC₅₀	4.8 μM Compound: 18	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
B16-F10	IC₅₀	106.4 μM Compound: OA	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
B16-F10	IC₅₀	106.4 μM Compound: I, Oleanolic acid	Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 29471121]
B16-F10	IC₅₀	106.4 μM Compound: I; OA; Oleanolic and	Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
B16-F10	IC₅₀	106.4 μM Compound: 1, OA, Oleanolic acid	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 24480359]
B16-F10	IC₅₀	388.3 μM Compound: 3; OA	Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
Bel-7402	IC₅₀	59.94 μM Compound: 1; OA	Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
Bel7402/5-FU	IC₅₀	> 200 μM Compound: 1; OA	Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Bel7402/5-FU cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
BEL-7404 tumor cell line	IC₅₀	57.89 μM Compound: 1, OA	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
BGC-823	IC₅₀	2.59 μM Compound: 1, OA	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23434227]
BGC-823	IC₅₀	23.74 μM Compound: 1	Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
BMDC	IC₅₀	> 50 μM Compound: 22	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
BMDC	IC₅₀	> 50 μM Compound: 22	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
BMDC	IC₅₀	> 50 μM Compound: 22	Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA	[PMID: 23484668]
CAPAN-1	IC₅₀	50.1 μM Compound: OA	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
CHO	EC₅₀	2.25 μM Compound: 2	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COLO 205	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 30199257]
COLO 320	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay Cytotoxicity against human COLO320 cells after 24 hrs by MTT assay	[PMID: 30199257]
COS-1	EC₅₀	0 μM Compound: 2	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DLD-1	IC₅₀	> 100 μM Compound: 4	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	> 200 μM Compound: 4	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
DU-145	IC₅₀	124 μM Compound: 10	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	CC₅₀	65.6 μM Compound: 10	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
FaDu	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
FaDu	EC₅₀	66.7 μM Compound: OA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
FaDu	EC₅₀	75.4 μM Compound: OA	Cytotoxicity against human FADU cells after 96 hrs by SRB assay Cytotoxicity against human FADU cells after 96 hrs by SRB assay	[PMID: 26750249]
FaDu	EC₅₀	75.4 μM Compound: 1; OA	Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
H9	EC₅₀	1.7 μg/mL Compound: 1	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 9748372]
H9	IC₅₀	21.8 μg/mL Compound: 1	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
H9	IC₅₀	47.8 μM Compound: 3	Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days	[PMID: 11141100]
HCT-116	GI₅₀	> 100 μM Compound: 27	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HCT-116	IC₅₀	> 150 μM Compound: OA	Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay Cytotoxicity against human HCT116 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
HCT-116	IC₅₀	32.4 μM Compound: OA	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
HCT-116	IC₅₀	4.8 μM Compound: Oleanolic acid	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 20951582]
HEK293	CC₅₀	> 500 μM Compound: 10	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	> 500 μM Compound: 10	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	329 μM Compound: 9	Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by cell titer-blue assay	[PMID: 26473275]
HEL	EC₅₀	> 1 μM Compound: OA	Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33569941]
HeLa	IC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HeLa	IC₅₀	> 100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24487188]
HeLa	CC₅₀	> 500 μM Compound: 10	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	204.5 μM Compound: 10	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	31.38 μM Compound: OA	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HeLa	IC₅₀	4 μM Compound: 1	Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs Inhibition of N-terminal 6His-tagged human AKR1B10 overexpressed in human HeLa cells assessed as inhibition of [1-14C]farnesol reduction pretreated for 2 hrs before [1-14C]farnesol challenge measured after 6 hrs	[PMID: 21561086]
HEp-2	CC₅₀	> 500 μM Compound: 10	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	> 500 μM Compound: 10	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HepG2	IC₅₀	> 10 μM Compound: 16	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HepG2	IC₅₀	> 100 μM Compound: 11	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
HepG2	IC₅₀	14.72 μM Compound: OA	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HepG2	IC₅₀	15.9 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
HepG2	IC₅₀	165 μM Compound: 10	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	211.8 μM Compound: OA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
HepG2	IC₅₀	211.8 μM Compound: I, Oleanolic acid	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 29471121]
HepG2	IC₅₀	211.8 μM Compound: I; OA; Oleanolic and	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
HepG2	IC₅₀	51.4 μM Compound: OA	Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
HepG2 2.2.15	CC₅₀	731.2 μM Compound: D1; OA	Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 29627260]
HL-60	IC₅₀	> 30 μM Compound: 1; OA	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29133061]
HL-60	IC₅₀	> 50 μg/mL Compound: oleanolic acid	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 10514313]
HL-60	IC₅₀	14.75 μM Compound: 1; OA	Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
HL-60	IC₅₀	16.17 μM Compound: OA	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HL-60	IC₅₀	36.4 μM Compound: OA	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
HL-60	IC₅₀	54.56 μM Compound: 1, OA	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
HL-60	IC₅₀	77.48 μM Compound: Oleanolic acid	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 20951582]
HL60/ADR	IC₅₀	28.75 μM Compound: 1; OA	Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HL60/ADR cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
HSC-T6	EC₅₀	59.6 nM Compound: 139	Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay	[PMID: 29353722]
HT-29	EC₅₀	> 10 μM Compound: 8	Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay	[PMID: 33248849]
HT-29	IC₅₀	> 10 μM Compound: 8	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
HT-29	IC₅₀	> 10 μM Compound: 8	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
HT-29	IC₅₀	> 100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 24487188]
HT-29	IC₅₀	> 30 μM Compound: 1; OA	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29133061]
HT-29	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
HT-29	EC₅₀	> 30 μM Compound: 2	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 28033541]
HT-29	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
HT-29	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
HT-29	EC₅₀	38.8 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 26750249]
HT-29	IC₅₀	38.8 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24361521]
HT-29	EC₅₀	38.8 μM Compound: 1; OA	Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
HT-29	IC₅₀	429.9 μM Compound: OA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
HT-29	IC₅₀	429.9 μM Compound: I, Oleanolic acid	Growth inhibition of human HT-29 cells after 72 hrs by MTT assay Growth inhibition of human HT-29 cells after 72 hrs by MTT assay	[PMID: 29471121]
HT-29	IC₅₀	429.9 μM Compound: I; OA; Oleanolic and	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
HT-29	EC₅₀	44.9 μM Compound: OA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
J774	IC₅₀	130.5 μM Compound: 8	Cytotoxicity against mouse J774 cells by alamar blue assay Cytotoxicity against mouse J774 cells by alamar blue assay	[PMID: 17637068]
J774.A1	IC₅₀	35.2 μM Compound: 1, Oleanolic acid	Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
J774.A1	IC₅₀	87.22 μM Compound: 1, Oleanolic acid	Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control	[PMID: 25113933]
Jurkat	EC₅₀	> 1 μM Compound: OA	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33569941]
K562	EC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33569941]
K562	IC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]
K562	IC₅₀	> 200 μM Compound: 1; OA	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
K562	IC₅₀	58.13 μM Compound: 1, OA	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
K562/Adr	IC₅₀	> 200 μM Compound: 1; OA	Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
KB	IC₅₀	> 10 μM Compound: OA	Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
KB	IC₅₀	> 100 μM Compound: 11	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
KB	CC₅₀	> 500 μM Compound: 10	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	> 500 μM Compound: 10	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
L02	IC₅₀	> 200 μM Compound: 1; OA	Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
L5178Y	IC₅₀	> 10 μM Compound: 6	Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay Antiproliferative activity against mouse L5178Y cells after 72 hrs by MTT assay	[PMID: 30199257]
L5178Y	IC₅₀	> 10 μM Compound: 6	Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay Antiproliferative activity against mouse L5178Y cells harboring human ABCB1 after 72 hrs by MTT assay	[PMID: 30199257]
Lewis lung carcinoma cell line	IC₅₀	> 150 μM Compound: 9	Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay Cytotoxicity activity against mouse LLC cells after 48 hrs by MTT assay	[PMID: 19618898]
Lewis lung carcinoma cell line	IC₅₀	810.1 μM Compound: 3; OA	Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
LN-229	IC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
Lu1	IC₅₀	> 100 μM Compound: 11	Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
M14	IC₅₀	82 μM Compound: 5	Cytotoxicity against human M14 cells after 48 hrs by MTT assay Cytotoxicity against human M14 cells after 48 hrs by MTT assay	[PMID: 21954959]
Macrophage	IC₅₀	> 40 μM Compound: 3	Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method Antiinflammatory activity in mouse macrophages assessed as inhibition of IFN-gamma-induced nitric oxide production after 48 hrs by Griess method	[PMID: 23837912]
Macrophage	IC₅₀	18.64 μM Compound: Oleanolic acid	Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay Anti-osteoclastogensis activity in BALB/c mouse bone marrow macrophage cells assessed as inhibition of RANKL/M-CSF-induced osteoclastogenesis by measuring osteoclasts number incubated for 11 days by TRAP staining based assay	[PMID: 36701870]
Macrophage	CC₅₀	29.69 μM Compound: Oleanolic acid	Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay Cytotoxicity against BALB/c mouse bone-marrow derived macrophage cells assessed as reduction in cell viability incubated for 11 days by MTT assay	[PMID: 36701870]
MCF-12A	IC₅₀	> 50 μM Compound: 1; OA	Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MCF12A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MCF7	IC₅₀	> 10 μM Compound: 16	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27797185]
MCF7	IC₅₀	> 10 μM Compound: OA	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MCF7	IC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	> 100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24487188]
MCF7	GI₅₀	> 100 μM Compound: 27	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	IC₅₀	> 100 μM Compound: 11	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	IC₅₀	> 150 μM Compound: OA	Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 24422538]
MCF7	IC₅₀	> 150 μM Compound: 9	Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19618898]
MCF7	IC₅₀	> 200 μM Compound: 1; OA	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
MCF7	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
MCF7	EC₅₀	> 30 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 28033541]
MCF7	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay	[PMID: 26177446]
MCF7	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
MCF7	CC₅₀	> 500 μM Compound: 10	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	> 500 μM Compound: 10	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	> 60 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24361521]
MCF7	GI₅₀	10.3 μM Compound: 1; OA	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MCF7	IC₅₀	12.6 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
MCF7	IC₅₀	12.7 μM Compound: 1; OA	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MCF7	IC₅₀	35.4 μM Compound: 1, OA	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23434227]
MCF7	EC₅₀	49.1 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
MCF7	EC₅₀	80 μM Compound: OA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 26750249]
MCF7	EC₅₀	80 μM Compound: 1; OA	Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
MDA-MB-231	IC₅₀	> 10 μM Compound: OA	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MDA-MB-231	IC₅₀	> 10 μM Compound: 8	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-231	IC₅₀	> 100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24487188]
MDA-MB-231	IC₅₀	> 50 μM Compound: 1; OA	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MDA-MB-231	CC₅₀	106 μM Compound: 10	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	134 μM Compound: 10	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	GI₅₀	17.6 μM Compound: 1; OA	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MDA-MB-231	IC₅₀	512.4 μM Compound: 3; OA	Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
MDA-MB-231	IC₅₀	67.87 μM Compound: 1, OA	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	10.1039/C2MD20051A
MDA-MB-435	IC₅₀	> 10 μM Compound: 8	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
MDA-MB-453	IC₅₀	> 100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay	[PMID: 24487188]
MDA-MB-468	IC₅₀	38.1 μM Compound: 1; OA	Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MDCK	CC₅₀	> 100 μM Compound: OA	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 40 hrs by Celltiter-Glo assay	[PMID: 31425909]
MDCK	CC₅₀	> 100 μM Compound: OA	Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability by CellTiter-Glo assay	[PMID: 34795865]
MDCK	IC₅₀	> 50 μM Compound: OA	Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by Antiviral activity against Influenza A virus A/Thailand/Kan353/2004(H5N1) pseudovirus infected in MDCK cells co-infected with HA/HIV assessed as inhibition of viral replication preincubated with virus for 30 mins followed by viral infection for 48 hrs by	[PMID: 27153348]
MDCK	CC₅₀	23.1 μM Compound: OA	Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay Cytotoxicity against MDCK cells assessed as cell death after 2 days by MTT assay	[PMID: 27153348]
ME-180	IC₅₀	> 100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human ME180 cells after 48 hrs by MTT assay Cytotoxicity against human ME180 cells after 48 hrs by MTT assay	[PMID: 24487188]
MRC5	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay	[PMID: 30199257]
NCI/ADR-RES	IC₅₀	> 200 μM Compound: 1; OA	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31673307]
NCI-H1975	IC₅₀	> 10 μM Compound: OA	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	> 10 μM Compound: OA	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H460	IC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay	[PMID: 34352711]
NCI-N87	IC₅₀	> 10 μM Compound: 16	Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay	[PMID: 27797185]
Neutrophil	IC₅₀	0.75 μM Compound: 15	Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins	[PMID: 21417387]
NIH3T3	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	[PMID: 30199257]
NIH3T3	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay	[PMID: 31718946]
NIH3T3	EC₅₀	> 30 μM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 28033541]
NIH3T3	EC₅₀	> 30 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
NIH3T3	EC₅₀	57.9 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
NIH3T3	EC₅₀	76.4 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 26750249]
NIH3T3	IC₅₀	76.4 μM Compound: OA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24361521]
NIH3T3	EC₅₀	76.4 μM Compound: 1; OA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
OVCAR-3	IC₅₀	> 10 μM Compound: 8	Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
PANC-1	IC₅₀	362.8 μM Compound: 3; OA	Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
PC-3	IC₅₀	> 100 μM Compound: 1, Oleanolic acid	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24487188]
PC-3	IC₅₀	> 30 μM Compound: 1; OA	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 29133061]
PC-3	IC₅₀	6.51 μM Compound: 1, OA	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 23434227]
PC-3	IC₅₀	72.74 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	10.1039/C6MD00061D
Raji	IC₅₀	449 nM Compound: Oleanolic acid	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation after 48 hrs	[PMID: 21620532]
RAW264.7	CC₅₀	145.47 μM Compound: Oleanolic acid	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36701870]
RAW264.7	IC₅₀	41.7 μM Compound: 1, Oleanolic acid	Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
RAW264.7	IC₅₀	89.12 μM Compound: 1, Oleanolic acid	Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control	[PMID: 25113933]
RAW264.7	IC₅₀	96.63 μM Compound: Oleanolic acid	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta level incubated for 48 hrs by ELISA assay	[PMID: 36701870]
Sf21	IC₅₀	> 40 μM Compound: 10	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]
Sf9	IC₅₀	> 20 μM Compound: OA	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	[PMID: 31718182]
Sf9	IC₅₀	> 20 μM Compound: OA	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	[PMID: 31718182]
Sf9	IC₅₀	> 20 μM Compound: OA	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	[PMID: 31718182]
SiHa	CC₅₀	108.7 μM Compound: 10	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	110.2 μM Compound: 10	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
T47D	IC₅₀	36.22 μM Compound: 1; OA	Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
U-87MG ATCC	IC₅₀	18.52 μM Compound: OA	Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
Vero	CC₅₀	> 500 μM Compound: 10	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	IC₅₀	> 500 μM Compound: 10	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
WI-38	IC₅₀	14.5 μM Compound: 10	Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38 VA13	IC₅₀	123 μM Compound: 10	Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
Z-138	IC₅₀	> 100 μM Compound: OA	Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis	[PMID: 34352711]

體外研究
(In Vitro)

Oleanolic Acid (OA) 以劑量依賴性和時間依賴性方式抑制肺癌細胞的增殖，同時增加 miR-122 豐度。CCNG1 和 MEF2D 這兩個假定的 miR-122 靶標被發(fā)現(xiàn)被 OA 處理下調(diào)^[1]。OA 在正常組織來源的細胞中誘導(dǎo)自噬而沒有細胞毒性。OA 誘導(dǎo)的自噬可降低 KRAS 轉(zhuǎn)化的正常細胞的增殖，并損害其侵襲和不依賴錨定的生長^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

小鼠模型實驗還表明，OA 通過誘導(dǎo)自噬抑制 KRAS 轉(zhuǎn)化的乳腺上皮細胞 MCF10A 來源的腫瘤異種移植物的生長^[2]。在所有測試的癌細胞中，MAPK 通路 (包括 p-38 MAPK、JNK 和 ERK) 的激活由 OA 以劑量和時間依賴性方式觸發(fā)。OA 誘導(dǎo) p38 MAPK 激活促進 Bax 和 Bim 的線粒體易位，并通過增強其磷酸化來抑制 Bcl-2 功能。OA 可誘導(dǎo)活性氧 (ROS) 依賴性 ASK1 激活，該事件對于癌細胞中 p38 MAPK 依賴性細胞凋亡是不可或缺的^[3]。這也證明了 p38 MAPK 敲低 A549 腫瘤是抗OA的生長抑制作用^[3]。在 OA 處理的 EAM 小鼠中，Treg 細胞的數(shù)量以及 IL-10 和 IL-35 的產(chǎn)生顯著增加，而促炎和促纖維化細胞因子顯著減少^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

456.70

Formula

C₃₀H₄₈O₃

CAS 號

508-02-1

性狀

固體

顏色

White to off-white

中文名稱

齊墩果酸；土當歸酸；石竹素；丁香油素

結(jié)構(gòu)分類

初始來源

內(nèi)源性代謝物

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細胞實驗：

DMF 中的溶解度 : 45.45 mg/mL (99.52 mM; 超聲助溶 (<60°C))

DMSO 中的溶解度 : 5 mg/mL (10.95 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.1896 mL	10.9481 mL	21.8962 mL
5 mM	0.4379 mL	2.1896 mL	4.3792 mL
10 mM	0.2190 mL	1.0948 mL	2.1896 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.5 mg/mL (1.09 mM); 懸濁液; 超聲助溶

此方案可獲得 0.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 5.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 0.5 mg/mL (1.09 mM); 懸濁液; 超聲助溶

此方案可獲得 0.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 5.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 0.5 mg/mL (1.09 mM); 澄清溶液

此方案可獲得 ≥ 0.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 5.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: ≥98.0%

選擇批次：

Data Sheet (650 KB) SDS (393 KB)

COA (289 KB) HNMR (262 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻

[1]. Zhao X, et al. Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis. Mol Cell Biochem. 2015 Feb;400(1-2):1-7. [Content Brief]

[2]. Liu J, et al. Oleanolic acid inhibits proliferation and invasiveness of Kras-transformed cells via autophagy. J Nutr Biochem. 2014 Nov;25(11):1154-60. [Content Brief]

[3]. Liu J, et al. p38 MAPK signaling mediates mitochondrial apoptosis in cancer cells induced by oleanolic acid. Asian Pac J Cancer Prev. 2014;15(11):4519-25. [Content Brief]

[4]. Martín R, et al. Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease. J Mol Cell Cardiol. 2014 Jul;72:250-62. [Content Brief]

Oleanolic acid 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO / DMF	1 mM	2.1896 mL	10.9481 mL	21.8962 mL	54.7405 mL
	5 mM	0.4379 mL	2.1896 mL	4.3792 mL	10.9481 mL
	10 mM	0.2190 mL	1.0948 mL	2.1896 mL	5.4741 mL
DMF	15 mM	0.1460 mL	0.7299 mL	1.4597 mL	3.6494 mL
	20 mM	0.1095 mL	0.5474 mL	1.0948 mL	2.7370 mL
	25 mM	0.0876 mL	0.4379 mL	0.8758 mL	2.1896 mL
	30 mM	0.0730 mL	0.3649 mL	0.7299 mL	1.8247 mL
	40 mM	0.0547 mL	0.2737 mL	0.5474 mL	1.3685 mL
	50 mM	0.0438 mL	0.2190 mL	0.4379 mL	1.0948 mL
	60 mM	0.0365 mL	0.1825 mL	0.3649 mL	0.9123 mL
	80 mM	0.0274 mL	0.1369 mL	0.2737 mL	0.6843 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Oleanolic acid508-02-1Oleanic acid Caryophyllin齊墩果酸土當歸酸石竹素丁香油素MAP3KAutophagyEndogenous MetaboliteHIVMAP kinase kinase kinase, MEKK, MAPKKKHuman immunodeficiency virusInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Oleanolic acid (Synonyms: 齊墩果酸; Oleanic acid; Caryophyllin)

Customer Review

Other Forms of Oleanolic acid:

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻

Oleanolic acid 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 MAP3K 亞型特異性產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

摩爾計算器

稀釋計算器

Oleanolic acid 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Oleanolic acid (Synonyms: 齊墩果酸; Oleanic acid; Caryophyllin)

Customer Review

Other Forms of Oleanolic acid:

Oleanolic acid 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻

Oleanolic acid 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

查看 MAP3K 亞型特異性產(chǎn)品:

查看 HIV 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

Oleanolic acid 相關(guān)抗體:

摩爾計算器

稀釋計算器

Oleanolic acid 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z